We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-4.07%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.61B
AUM Growth
-$1.09B
Cap. Flow
-$352M
Cap. Flow %
-4.08%
Top 10 Hldgs %
30.78%
Holding
207
New
16
Increased
51
Reduced
80
Closed
30

Top Buys

Rank Stock Value
1
OM icon
Outset Medical
OM
+$58.4M
2
BSX icon
Boston Scientific
BSX
+$41.2M
3
PACB icon
Pacific Biosciences
PACB
+$38.3M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$37.2M
5
CDNA icon
CareDx
CDNA
+$32.9M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$109M
2
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
+$75.3M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$73.9M
4
DHR icon
Danaher
DHR
+$66.3M
5
HUM icon
Humana
HUM
+$65.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.39%
2 Industrials 0.69%
3 Energy 0.03%
4 Technology 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBH icon
76
Zimmer Biomet
ZBH
$17.7B
$34.6M 0.4%
270,734
-8,592
-3% -$1.04M
VEEV icon
77
Veeva Systems
VEEV
$30.3B
$34.1M 0.4%
160,601
-4,354
-3% -$945K
BEAM icon
78
Beam Therapeutics
BEAM
$2.58B
$33.4M 0.39%
582,821
-30,000
-5% -$1.97M
HCM icon
79
HUTCHMED
HCM
$1.89B
$33.1M 0.38%
1,750,690
+673,820
+63% +$17.2M
EPIX
80
DELISTED
ESSA Pharma
EPIX
$31.1M 0.36%
5,034,814
– –
AUPH icon
81
Aurinia Pharmaceuticals
AUPH
$1.97B
$29.8M 0.35%
+2,405,825
New +$37.2M
AXSM icon
82
Axsome Therapeutics
AXSM
$12.4B
$29.8M 0.35%
719,482
+67,545
+10% +$2.09M
SRRK icon
83
Scholar Rock
SRRK
$5.71B
$28.2M 0.33%
2,184,425
-110,000
-5% -$1.88M
ILMN icon
84
Illumina
ILMN
$29.4B
$27.6M 0.32%
81,090
+3,856
+5% +$1.3M
CSTL icon
85
Castle Biosciences
CSTL
$749M
$27.3M 0.32%
+607,614
New +$25.1M
GBIO
86
DELISTED
Generation Bio
GBIO
$27M 0.31%
368,218
-19,000
-5% -$1.1M
TDOC icon
87
Teladoc Health
TDOC
$1.58B
$26.2M 0.3%
363,216
– –
NKTR icon
88
Nektar Therapeutics
NKTR
$2.39B
$25.9M 0.3%
320,560
+23,780
+8% +$3.52M
LEGN icon
89
Legend Biotech
LEGN
$4.3B
$24M 0.28%
660,069
+2,413
+0.4% +$95.3K
CVS icon
90
CVS Health
CVS
$137B
$23.5M 0.27%
232,355
+3,557
+2% +$374K
HOLX
91
DELISTED
Hologic
HOLX
$21.2M 0.25%
275,783
-303,641
-52% -$21.8M
RMD icon
92
ResMed
RMD
$28.3B
$20.9M 0.24%
86,349
-141
-0.2% -$34.1K
ESPR
93
DELISTED
Esperion Therapeutics
ESPR
$19.9M 0.23%
4,299,164
-220,000
-5% -$944K
TXG icon
94
10x Genomics
TXG
$5.87B
$19.2M 0.22%
252,859
+20,187
+9% +$1.77M
BNTX icon
95
BioNTech
BNTX
$22.6B
$19.1M 0.22%
111,766
-1,700
-1% -$286K
AVTR icon
96
Avantor
AVTR
$7.81B
$17.3M 0.2%
512,216
– –
NVRO
97
DELISTED
NEVRO CORP.
NVRO
$17.2M 0.2%
237,841
– –
MRSN
98
DELISTED
Mersana Therapeutics
MRSN
$15.8M 0.18%
158,160
-8,400
-5% -$981K
TMDX icon
99
Transmedics
TMDX
$2.5B
$15.7M 0.18%
581,029
– –
PHR icon
100
Phreesia
PHR
$632M
$15.3M 0.18%
580,498
-11,829
-2% -$362K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q1 2022 Portfolio in Review

As of Q1 2022, Bellevue Group held 207 positions worth $8.61B, down 11% from $9.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bellevue Group withdrew a net $352M in Q1 2022, closing 30 positions and reducing 80 holdings. Its most notable exit was VOCERA COMMUNICATIONS, INC., an estimated $75.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Aurinia Pharmaceuticals worth $29.8M.

  • Bellevue Group's largest Q1 2022 buy was Aurinia Pharmaceuticals: 2,405,825 shares worth $29.8M.
  • Bellevue Group added most to Outset Medical in Q1 2022, an estimated $58.4M increase.
  • Bellevue Group's biggest Q1 2022 reduction was Biogen, cutting an estimated $109M.
  • Bellevue Group fully exited VOCERA COMMUNICATIONS, INC. in Q1 2022, selling an estimated $75.3M.
  • Bellevue Group's ten largest holdings make up 31% of its $8.61B portfolio in Q1 2022.
  • Bellevue Group opened 16 new positions and closed 30 in Q1 2022.
  • Bellevue Group's portfolio value fell 11% quarter-over-quarter to $8.61B.

Based on Bellevue Group's 13F filing for Q1 2022, filed 13 May 2022.